Last reviewed · How we verify
SCYX-7158
At a glance
| Generic name | SCYX-7158 |
|---|---|
| Sponsor | Drugs for Neglected Diseases |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense (PHASE2, PHASE3)
- Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCYX-7158 CI brief — competitive landscape report
- SCYX-7158 updates RSS · CI watch RSS
- Drugs for Neglected Diseases portfolio CI